# Auvelity, approved in 2022 for depression, is Axsome's top-selling product.

*biotech · news · 2026-04-30 · Reuters*

## Key points

- Auvelity is now newly approved for treating agitation related to Alzheimer's disease.
- Auvelity is unlikely to receive the black box warning typically required for antipsychotics.
- Axsome expects to launch Auvelity's Alzheimer's indication in June at the same list price.
- Data from four late-stage trials showed Auvelity delayed relapse and reduced symptom worsening.

**Companies:** Axsome
**Countries:** United States, India

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-axsomes-drug-alzheimers-related-agitation-2026-04-30/)

---

Canonical: https://newsio.io/n/1270d90d-87f4-4e0e-8e28-0fcbbc853b28/auvelity-approved-in-2022-for-depression-is-axsomes-top-selling-product-it-works
Summarized by Newsio from Reuters. https://newsio.io/how-it-works